Abstract Cetuximab and panitumumab are monoclonal antibodies (mAbs) against epidermal growth factor receptor (EGFR) that are effective agents for metastatic colorectal cancer (mCRC). Cetuximab can prolong survival by 8. 2 months in RAS wild-type (WT) mCRC patients. https://atlanticknifers.shop/product-category/wallet/